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Background: Research ethics committees (RECs) are tasked to assess the risks and the benefits of a trial. Currently,
two procedure-level approaches are predominant, the Net Risk Test and the Component Analysis.
Discussion: By looking at decision studies, we see that both procedure-level approaches conflate the various risk-
benefit tasks, i.e., risk-benefit assessment, risk-benefit evaluation, risk treatment, and decision making. This conflation
makes the RECs’ risk-benefit task confusing, if not impossible. We further realize that RECs are not meant to do all
the risk-benefit tasks; instead, RECs are meant to evaluate risks and benefits, appraise risk treatment suggestions,
and make the final decision.
Conclusion: As such, research ethics would benefit from looking beyond the procedure-level approaches and
allowing disciplines like decision studies to be involved in the discourse on RECs’ risk-benefit task.
Keywords: Risk benefit assessment, Ethics committee, IRB, Decision theory, Net risk test, Component analysisBackground
Research ethics committees (RECs) are tasked to do a
risk-benefit assessment of proposed research with
human subjects for at least two reasons: to verify the
scientific/social validity of the research since an unscien-
tific research is also an unethical research; and to ensure
that the risks that the participants are exposed to are
necessary, justified, and minimized [1].
Since 1979, specifically through the Belmont Report,
the requirement for a “systematic, nonarbitrary analysis
of risks and benefits” has been called for, though up to
the present, commentaries about the lack of a generally
acknowledged suitable risk-benefit assessment method
continue [1]. The US National Bioethics Advisory
Commission (US-NBAC), for example, stated the follow-
ing in its 2001 report on Ethical and Policy issues in
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reproduction in any medium, provided the orAn IRB’s[1] assessment of risks and potential benefits
is central to determining that a research study is
ethically acceptable and would protect participants,
which is not an easy task, because there are no clear
criteria for IRBs to use in judging whether the risks of
research are reasonable in relation to what might be
gained by the research participant or society [2].
The lack of a universally accepted risk-benefit assess-
ment criteria does not mean that the research ethics
literature says nothing about it. Within this same 2001
report, the US-NBAC recommended Weijer and Miller’s
Component Analysis to RECs in evaluating clinical
researches. As a reaction to Weijer and P. Miller, Wend-
ler and F. Miller proposed the Net Risk Test. For
convenience sake, we shall use the term “procedure-level
approaches” [3] to refer to the models of Weijer et al.
and Wendler et al.
In spite of their ideological differences, both
procedure-level approaches are procedural in the sense
that both approaches propose a step-by-step process in
doing the risk-benefit assessment. In this paper, we shalll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ested in their similarities. We are of the position that
both approaches fall short of providing an evaluation
procedure that is systematic and nonarbitrary precisely
because they conflate the various risk-benefit tasks, i.e.,
risk-benefit analysis, risk-benefit evaluation, risk treat-
ment, and decision making [4-6]. As such, we recom-
mend clarifying what these individual tasks refer to, and
to whom these tasks must go. Lastly, we shall assert that
RECs would benefit by looking into the current inputs
of decision studies on the various risk-benefit tasks.
The procedure-level approaches
Charles Weijer and Paul Miller’s Component Analysis
(Figure 1) requires research protocol procedures or
“components” to be evaluated separately, since the
probable benefits of one component must not be used to
justify the risks that another component poses [2]. In
this system, RECs would need to make a distinction
between procedures in the protocol that are with and
those that are without therapeutic warrant since thera-
peutic procedures would need to be analyzed differently
compared to those that are non-therapeutic. It works on
the assumption that a therapeutic warrant, that is, the





















Figure 1 Component Analysis [7,9].from a procedure, would justify more risks for the parti-
cipants [7]. As such, therapeutic procedures ought to be
evaluated based on the following conditions, in chrono-
logical order: that clinical equipoise exists, that is, that
there is an “honest professional disagreement in the
community of expert practitioners as to the preferred
treatment” [8]; the “procedure is consistent with compe-
tent care; and risk is reasonable in relation to potential
benefits to subjects” [7]. Non-therapeutic procedures, on
the other hand, would need to be evaluated on the
following conditions: the “risks are minimized and are
consistent with sound scientific design; risks are reason-
able in relation to knowledge to be gained; and if vulner-
able population is involved, (there must be) no more
than minor increase over minimal risk” [7]. Lastly, the
REC would need to determine if both therapeutic and
non-therapeutic procedures are acceptable [7]. If all
components “pass”, then the “research risks are reason-
able in relation to anticipated benefits” [7].
David Wendler and Franklin Miller, on the other hand,
developed the Net-Risk Test (Figure 2) as a reaction to
the Component Analysis. This system requires RECs to
first “minimize the risks of all interventions included in
the study” [10]. After which, the REC ought to review






















and enhance its benefits
Does the intervention offer a
potential for clinical benefit that
compensates for its risks and
burdens?
Yes No
Acceptable Are the net risks sufficiently
low and justified by the social
value of the intervention?
Yes No
Acceptable Not acceptable
Figure 2 The Net Risk Test [10].
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potential for clinical benefit that compensates for its
risks and burdens” [10]. If an intervention does offer a
potential benefit that can compensate for the risks, then
the intervention is acceptable; otherwise, the REC would
need to determine whether the net risk is “sufficiently
low and justified by the social value of the intervention”
[10]. By net risk, they refer to the “risks of harm that are
not, or not entirely, offset or outweighed by the potential
clinical benefits for participants” [11]. If the net risks are
sufficiently low and are justified by the social value of
the intervention, then the intervention is acceptable;
otherwise, it is not. Lastly, the REC would need to “cal-
culate the cumulative net risks of all the interven-
tions. . .and ensure that, taken together, the cumulative
net risks are not excessive” [10].
Recently, Rid and Wendler elaborated the Net Risk
Test through a seven-step framework (see Figure 3) that
is meant to offer a chronological, “systematic and
comprehensive guidance” for the risk-benefit evaluations
of RECs [11]. As we could see from Figure 3, most of
the steps are the same as that of the previously explained
Net Risk Test; the main addition of the framework is the
first step, which is to ensure and enhance the study’s
social value. In this first step, Rid and Wendler meantthat RECs, at the start of their risk-benefit evaluation,
ought to “ensure the study methods are sound”; “ensure
that the study passes a minimum threshold of social
value”; and “enhance the knowledge to be gained from
the study” [11]. It is only after the social value of the
study has been identified, evaluated, and enhanced could
the RECs identify the individual interventions and then
go through the other steps, i.e., the steps we have earlier
discussed in the Net Risk Test.
The procedure-level approaches and the
conflation of risk-benefit analysis, risk-benefit
evaluation, risk treatment, and decision making
These procedure-level approaches may be credited for
providing some form of a framework for the risk-benefit
assessment tasks of RECs. They have also provided RECs
with a framework that includes and puts into perspective
certain ethical concepts that may or may not have been
considered in REC evaluations, but are now procedurally
necessary concepts. Weijer and Miller, for example,
made it necessary for RECs to always consider thera-
peutic warrant, equipoise, and minimal risk when evalu-
ating the risk-benefit balance of a study. Wendler and
Miller on the other hand, provided RECs with the
concept of net risk. In spite of these contributions, these
Step1: Ensure and enhance the study’s social value
Step2: Identify the research interventions
Step3: Evaluate and reduce the risks to participants
Step4: Evaluate and enhance the potential benefits for participants
Step5: Evaluate whether the interventions pose net risks
Step6: Evaluate whether the net risks are justified by the potential benefits of other interventions
Step7: Evaluate whether the remaining net risks are justified by the study’s social value
Figure 3 Seven-step framework for risk-benefit evaluations in biomedical research [11].
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benefit analysis, risk-benefit evaluation, risk treatment,
and decision making can all be conflated. This, in our
view, is a major error that ought to be corrected since
from this error flow other problems, problems that
unavoidably make the procedures unsystematic and arbi-
trary. To substantiate our view, we first have to make a
necessary detour by discussing the distinction between
risk-benefit analysis, risk-benefit evaluation, risk treat-
ment, and decision making [4,5]. After which, we shall
show how the conflation is present in the procedure-
level approaches and how such a conflation leads to
difficult problems.
Distinction between risk-benefit analysis, risk-benefit
evaluation, risk treatment, and decision making
Decisions on benefits and risks in fact involve four activ-
ities: risk-benefit analysis, risk-benefit evaluation, risk
treatment, and decision making [4-6]. In the current
debate, these terms are used as if they are interchange-
able. Precisely because these four activities have four
different demands, it must be made clear that the prob-
lem is not merely on terminological preference; that is,
the problem cannot be solved by simply “agreeing” to
use one term over another. In risk studies, the risk-
benefit task concretely demands four separate activities
[4,6]. Hence, these terms are not interchangeable, and
their order must be chronological. The distinctions
among these tasks and the necessity of their chrono-
logical ordering are as follows.
Risk-benefit analysis refers to the “systematic use of
information to identify initiating events, causes, and
consequences of these initiating events, and express risk
(and benefit)” [4]. This, risk-benefit analysis refers to 1.)
gathering of risk and benefit events, causes, and conse-
quences; and 2.) presenting this wealth of information in
a systematic and comprehensive way, in accordance with
the purpose why such information is systematized in the
first place. There are a number of risk analysis methods
such as fault tree analysis, event tree analysis, Bayesian
networks, Monte Carlo simulation, and others [4]. The
multi criteria decision analysis (MCDA) method, men-
tioned by the EU Committee for Medicinal Products for
Human Use (CHMP) in the Reflection Paper on Benefit
Risk Assessment Methods in the Context of theEvaluation of Marketing Authorization Applications
of Medicinal Products for Human Use [12], proposes
the use of a value tree in analyzing the risk-benefit bal-
ance of a drug, for example. Adjusted to drug trials, a
drug trial risk-benefit analysis value tree could look like
(Figure 4).
In this value tree (Figure 4), we used King and
Churchill’s typology of harms and benefits [1]. From
each of the branches, the risk analyst would fill in infor-
mation about a specific study. Of course, there could be
more than one input under each category, depending on
the nature of the drug trial being analyzed. Also, this
value tree serves as an example; this is not the only way
that benefits and risks may be analyzed within the con-
text of drug trials. The best way to analyze risks and
benefits within this context is something that ought to
be further discussed and developed. Our aim is simply
to show that a method such as a value tree is capable of
encapsulating and framing the multidimensional nature
of the causes and consequences of the benefits and risks
of a study within one “tree.” This provides a functional
risk-benefit picture from which the risks and the benefits
may be evaluated, i.e., risk-benefit evaluation.
Risk-benefit evaluation refers to the “process of com-
paring risk (and benefit) against given risk (and benefit)
criteria to determine the significance of the risk (and the
benefit)” [4]. There are a number of methods to evaluate
benefits and risks. Within the MCDA model for ex-
ample, the “identification of the risk-benefit criteria; as-
sessment of the performance of each option against the
criteria; the assignment of weight to each criterion; and
the calculation of the weighted scores at each level and
the calculation of the overall weighted scores”[13] would
constitute risk evaluation. The multriattribute utility the-
ory (MAUT) is yet another example of an evaluation
method. The MAUT is a theory that is basically “con-
cerned with making tradoffs among different goals” [14].
This theory factors in human values, values defined as
“the functions to use to assign utilities to outcomes”
[14]. From the value tree “inputs,” the evaluator would
then need to assign weights to each of these inputs. The
purpose of plugging in weights is to establish the im-
portance of each input, according to the evaluators. This
is tantamount to establishing criteria, or identifying and

































Input 2 Input 3 Input 4
Input 5 Input 6
Input 7…
Figure 4 Risk-benefit analysis value tree.
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ical values as the utility values of those that are being
evaluated. These values would be multiplied to the
weight. The latter values, when summed, would consti-
tute the total utility value. To illustrate, if, for example,
an REC wishes to make an evaluation of a psychotropic
study drug and the standard drug, an REC may come up
with MAUT chart like (Table 1).
Just like the value tree, our purpose is not to endorse
only one way of doing the evaluation. Our purpose is
merely to illustrate that such a decision study tool is
capable of explicitly showing the following: a.) the inputs
that the evaluators think must play a role in the evalu-
ation; b.) the values of the evaluators, through the scores
they have provided; c.) the importance they give to eachof the factors/inputs through the weights that they have
provided, d.) how the things compared (in this case, the
study drug and the standard drug) fare given a, b and c;
and e.) a global perspective of what a, b, c, and d
amount to, i.e., through the total utility value.
In the risk-benefit literature in research ethics, we find
statements that such an algorithm is undesirable because
it “yields one and only one verdict about the risk-benefit
profile of each possible protocol” [11]. On this issue,
CMHP’s Reflection is instructive. The scores in quantita-
tive evaluations are valuable not because of some abso-
lute value, but because these scores can
. . .focus the discussion by highlighting the
divergences between the assessors and stakeholders
concerning choice for weights. The benefit of such























Study drug 50 40 90 50 100 100 50 (1) + 40 (1) +
90 (.9) + 50 (.5) +
100 (.4) + 100
(.4) + . . .
Standard
drug
70 80 40 100 100 50 70 (1) + 80 (1) +
40 (.9) + 100 (.5)
+ 50 (.4) + . . .
WEIGHT 1.0 1.0 .9 .5 .4 .4
Bernabe et al. BMC Medical Ethics 2012, 13:6 Page 6 of 9
http://www.biomedcentral.com/1472-6939/13/6analysis methods is that the degree and nature of
these divergences can be assessed, even in advance of
any compound’s review. The same method might be
used with the weights (e.g., of different stakeholders)
and make both the differences and the consequences
of those differences more explicit. If the analyses
agree, decision-makers can be more comfortable with
a decision. If the analyses disagree, exact sources of
the differences in view will be identified, and this will
help focus the discussion on those topics [12].
Thus, the scores are meant to allow the evaluators to
know each others’ values, similarities, differences, and
divergences. The divergences and differences could aid
in focusing the REC discussion and figure out problem
areas in a deliberate, transparent, coherent, and less in-
tuitive manner [15].
Risk-benefit analysis and evaluation together constitute
risk-benefit assessment [4].
Once risks and benefits have been evaluated versus the
evaluators’ given criteria, risk evaluation allows evalua-
tors to decide “which risks need treatment and which do
not” [6]. In decision studies, amplifying benefits and
modifying risks are possible only after a global under-
standing of it through risk assessment has been
achieved. Thus, after risk-benefit assessment comes risk
treatment. By risk treatment, we refer to the “process of
selection and implementation of measures to modify
risk. . .measures may include avoiding, optimizing, trans-
ferring, or retaining risk” [4]. In terms of trials, risk
treatment would refer to enhancing the trial’s social
value, reducing the risks to the participants, and enhan-
cing the participants’ benefits [11]. There may be con-
cerns especially from REC members who have been used
to minimizing risk immediately after its identification
that this process necessitates them to suspend such
move until risk evaluation is done, a procedure that maybe counter-intuitive for some. However, the process of
“immediately cutting the risks” also have passed through
the process of evaluation, although intuitively and impli-
citly. An REC member who says that the risks of a cer-
tain procedure may be minimized or that the risks are
unnecessary given the research question has already im-
plicitly gone through a personal evaluation of what is
and what is not necessary in such a clinical trial.
After investigating on the possibilities to modify risk
and amplify the benefits, the decision makers would
then have to finally decide whether the risks of the trial
are justified given the benefits. By decision making, we
refer to the final discussion of the REC on whether ben-
efits truly outweigh risks, i.e., given all the information
provided, are the risks of the trial ethically acceptable
due to the merits of the probable benefits?
It is important to note that in the risk literature [4,13],
the CHMP Reflection [12], and the CIOMS report [16],
the risk-benefit tasks are assumed to be done interde-
pendently and that the tasks are reflective of various
values, interests, and ethical perspectives. At least for
marketing authorization and marketed drug evaluation
purposes, the sponsor and/or the investigator are
assumed to be responsible for risk-benefit assessment
and to a certain extent, the proposal of risk treatment
measures. It makes a lot of sense that the sponsor ought
to be responsible for risk analysis precisely because in
this task, “experts on the systems and activities being
studied are usually necessary to carry out the analysis”
[4]. The regulatory authorities, on the other hand, are
expected to provide guidelines for the risk-benefit ana-
lysis criteria. They also ought to provide their own ver-
sion of risk-benefit evaluation to determine areas of
divergences and differences, to extensively discuss risk
treatment measures and options, and finally to deliberate
and decide based on all these inputs.
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procedure-level approaches
At the most superficial level, we notice that Wendler
and Rid used the terms “risk-benefit assessment” and
“risk-benefit evaluation” interchangeably to refer to the
one and the same Net Risk Test [11,17]. Nevertheless, it
could be argued that this is just a matter of misuse of
terms, and that such does not substantially affect the ap-
proach that is proposed. Thus, we would need to look
deeper into the Net Risk Test to justify our claim that it
conflates the various risk-benefit tasks.
In the latest seven-step framework of the Net Risk
Test, what ought to be a framework for risk-benefit
evaluation of RECs ended up incorporating aspects of
risk-benefit assessment, risk treatment, and decision
making. The first step, that is, ensuring and enhancing
the study’s social value, is risk treatment. The second
step, that is, identifying the research interventions, is
risk analysis. The third and fourth steps, which are the
evaluation and reduction of risks to participants, and the
evaluation and enhancing of potential benefits to partici-
pants, both fall into risk-benefit evaluation and risk
treatment. It is worthwhile to note that in the Net Risk
Test, the evaluation and the treatment of risks and bene-
fits were not preceded by the identification of these risks
and benefits; instead, prior to the third and fourth steps
is the step to identify research interventions, a necessary
but incomplete step in risk-benefit analysis. The fifth
step, that is, the evaluation whether the interventions
pose net risks, is risk-benefit evaluation. The sixth step,
which is to evaluate whether the net risks are justified by
the potential benefits of other interventions, is decision
making. The last step, which is to evaluate whether the
remaining net risks are justified by the study’s social
value, is also decision making. Thus, the Net Risk Test
in principle encompasses all the risk-benefit tasks with-
out taking into account the distinctions, the chrono-
logical order among the various tasks, nor the division
of labor in the various risk-benefit tasks.
The Component Analysis, just like the Net Risk Test,
does the same conflation. In the process of distinguishing
procedures into either therapeutic or non-therapeutic, the
REC members would first need to identify the procedures
to assess, i.e., risk analysis. The REC members would then
need to evaluate therapeutic procedures differently
compared to non-therapeutic procedures. Therapeutic
procedures have to be evaluated on whether clinical
equipoise exists, and whether the procedure is consistent
with competent care. These two criteria may be consid-
ered as ethical principles that ought to be present in the
deliberation towards decision making. Thus, these are
decision making tasks. Next, the REC members would
need to determine if the therapeutic procedure is reason-
able in relation to the potential benefits to subjects. SinceREC members need to answer questions of “reasonability,”
this is a decision making task that presupposes risk-
benefit evaluation. Non-therapeutic procedures, on the
other hand, would necessitate the assessor to evaluate if
risks are minimized and if risks are consistent with sound
scientific design. This is risk treatment. Next, the assessor
would need to verify if the risk of the non-therapeutic pro-
cedure is reasonable in relation to knowledge to be gained.
Again, this is a decision making task that presupposes
risk-benefit evaluation. In cases where vulnerable patients
are involved, the REC members would need to verify if no
more than minor increase over minimal risk is involved;
this is a discussion that is likely to be present in the delib-
eration towards decision making, which also presupposes
risk-benefit evaluation. Lastly, the assessor would need to
make a decision if both therapeutic and non-therapeutic
procedures pass. This is decision making. Hence, again,
what we have is a system that touches on each of the risk-
benefit tasks without making a distinction among the
various tasks.
Since the risk-benefit tasks are conflated, the various
tasks are necessarily simplified and confused. We have
seen that the various risk-benefit tasks are resource
intensive (since various experts must be involved),
necessarily complex (since a drug trial is rarely simple),
and time consuming. This is the reason why they are
done separately. To conflate the various tasks into one
system that ought to be accomplished within the few
hours that the REC convenes is an impossibility.
Precisely because of this conflation, plus the consider-
ation that all the risk-benefit tasks ought to be done
within the time restrictions of an REC, both procedure-
level approaches cursorily and confusedly “accomplish”
the various tasks. As such, we cannot expect the
procedure-level approaches to have the same level of ro-
bustness, transparency, explicitness, and coherence as
the various approaches of decision studies have. Neither
of the procedure-level approaches could have the same
robustness that the value-tree had, for example, in
expressing and illustrating the relations between the na-
ture, cause, consequences, as well as the uncertainties,
of both risk and benefit components. Neither is also
transparent, explicit, and rigorous enough to capture the
acceptable risk definitions and the various weights and
scores that are reflective of the various values and ethical
dispositions that the MAUT method provided. The two
procedure-level approaches simply do not require eva-
luators to be explicit in terms of their evaluative values.
Though risk treatment is largely present in both
procedure-level approaches, risk treatment, at least in
the Net Risk Test, is sometimes confounded with risk
evaluation. In the procedure-level approaches, RECs
would also not have the benefit of systematically focus-
ing the discussion on divergences and differences that a
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the conflation and confusion of the various risk-benefit
tasks, REC members are left to their own devices and
intuition to decide on what is important to discuss and
which is not, and eventually, to decide if the risks are
justifiable relative to the benefits. Such a “procedure”
could be categorized as a “taking into account and bear-
ing in mind” process, a process that Dowie rightfully
criticized as vague, general, and plainly intuitive [15].
Recommendations
We have seen that the methods from decision studies
are more robust, transparent, and coherent than any of
the procedure-level approaches. This is not surprising
considering the fact that decision studies have been uti-
lized in many various fields for quite some time now.
The robustness of the decision studies methods stems
from the clear distinction between risk-benefit analysis,
risk-benefit evaluation, risk treatment, and decision
making. In decision studies, each of the risk-benefit tasks
is a system in itself that ought not to be conflated. In
addition, in contrast to “taking into account and bearing
in mind” processes, decision studies encourage the
exposure of beliefs and values [15] precisely because it is
from this explicitness that discussions can be defined
and ordered. As such, we recommend the following:
a. RECs should make clear what their task is. RECs do
not have the time and are not in the best position to
do risk analyses. As such, risk analysis must be a
task for the sponsor. As regards risk evaluation,
RECs ought to provide their own risk-benefit
evaluation to pair with the sponsor’s/investigator’s
evaluation since this is the best way to systematically
point out areas of divergence/convergence. These
areas would aid in putting order in REC discussions.
The evaluation of risk treatment suggestions and
possibly coming up with a revised or different risk
treatment appraisal ought to also form part of REC
discussions. Lastly, it is obviously the REC’s task to
make the final decision on whether the risks of the
trial are justified given the benefits.
b. Precisely because such a clarification of tasks is so
essential if the REC is to function efficiently, RECs
must look into how decision studies may be
incorporated in its risk-benefit tasks. This is
something we will do in our next article. For now, it
is imperative to lay the theoretical groundwork for
the urgency of such incorporation.
c. The procedure-level approaches emphasize on the
role of the various ethical concepts such as net risk,
minimum risk, clinical equipoise, in the risk-benefit
task of RECs. These are legitimate concerns;
nevertheless, RECs must know when these conceptsplay a role in the various risk-benefit tasks. Minimal
risk, for example, is a concept that ought to be
present in risk treatment and/or deliberation
towards final decision making.
Conclusion
Both the Net Risk Test and the Component Analysis
conflate risk-benefit analysis, risk-benefit evaluation, risk
treatment, and decision making. This makes the risk-
benefit task of RECs confusing, if not impossible. It is
necessary to make a distinction between these four
different tasks if RECs are to be clear about what their
task truly is. By looking at decision studies, we realize
that RECs ought to evaluate risks and benefits, appraise
risk treatment suggestions, and make the final decision.
Further clarification and elaboration of these tasks
would necessitate research ethicists to look beyond the
procedure-level approaches. It further requires research
ethicists to allow decision studies discourses into the
current discussion on the risk-benefit tasks of RECs.
Admittedly, this would take a lot of time and research
effort. Nevertheless, the discussion on the REC’s risk-
benefit task would be more fruitful and democratic if
research ethics opens its doors to other disciplines that
could truly help clarify risk-benefit task distinctions.
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